Abstract
Single photon emission computed tomography (SPECT) perfusion brain scans using123I-N-isopropyl-p-iodoamphetamine (123I-IMP) were performed in three patients with the neuroleptic malignant syndrome (NMS). In two accumulation was increased in the left basal ganglia and decreased in the right on the early images during the active phase of NMS; this asymmetry was not seen after recovery. In the third patient two examinations were performed during the active phase; on the first, increased accumulation of123I-IMP in the left basal ganglia was found on the early images, but on the second, increased accumulation of tracer was found in the right basal ganglia on the delayed images. These abnormalities disappeared after improvement of the NMS. These results suggest that a disturbance in the basal ganglia is related to the development of NMS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Delay J, Deniker P (1968) Drug-induced extrapyramidal syndromes. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology: diseases of the basal ganglia. Elsevier-North Holland, New York, pp 248–266
Levenson JL (1985) Neuroleptic malignant syndrome. Am J Psychiatry 142: 1137–1145
Addonizio G, Susman VL, Roth SD (1987) Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 22: 1004–1020
Rosenberg MR, Green M (1989) Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med 149: 1927–1931
Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S (1983) Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. Ann Neurol 14: 89–90
Henderson VW, Wooten GF (1981) Neuroleptic malignant syndrome: A pathogenetic role for dopamine receptor blockade? Neurology 31: 132–137
Toru M, Matsuda O, Makiguchi K, Sugano K (1981) Neuroleptic malignant syndrome-like state following withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 169: 324–327
Chang LT (1978) A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 25: 638–643
De Reuck J, Van Aken J, Van Landegem W, Colardyn F (1991) Positron emission tomographic studies of changes in cerebral blood flow and oxygen metabolism in neuroleptic malignant syndrome. Eur Neurol 31: 1–6
Güell A, Géraud G, Jauzac Ph, Victor G, Arné-Bès MC (1982) Effects of a dopaminergic agonist (Piribedil) on cerebral blood flow in man. J Cereb Blood Flow Metabol 2: 255–257
Winchell HS, Horst WD, Braun L, Oldendorf WH, Hattner R, Parker H (1980) N-isopropyl-(123I)p-iodoamphetamine: singlepass brain uptake and washout; binding to brain synaptosomes and localization in dogs and monkey brain. J Nucl Med 21: 947–952
Kuhl DE, Barrio JR, Huang SC, Selin C, Ackermann RF, Lear JL, Wu JL, Lin TH, Phelps ME (1982) Quantifying local cerebral blood flow by N-isopropyl-p-(123I)iodoamphetamine (IMP) tomography. J Nucl Med 23: 196–203
Ueda T, Kinoshita K, Watanabe K, Hoshi H, Jinnouchi S (1988) Early and delayed single photon emission CT in various cerebral diseases using N-isopropyl-p-(123I)iodoamphetamine. Neuroradiology 30: 123–131
Creutzig H, Schober O, Gielow P, Friedrich R, Becker H, Dietz H, Hundeshagen H (1986) Cerebral dynamics of N-isopropyl-(123I)p-iodoamphetamine. J Nucl Med 27: 178–183
Tsukada M, Kuwabara Y, Ichiya Y, Otsuka M, Tahara T, Miyake Y, Mizuguchi M, Gunasekera R, Masuda K (1989) Evaluation of the significance of “redistribution” in I-123 IMP SPECT in cerebrovascular disorders — a comparative study with PET. Eur J Nucl Med 15: 746–749
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nisijima, K., Matoba, M. & Ishiguro, T. Single photon emission computed tomography with123I-IMP in three cases of the neuroleptic malignant syndrome. Neuroradiology 36, 281–284 (1994). https://doi.org/10.1007/BF00593260
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00593260